Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population
Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population
复制标题
DOI：
10.1080/00365520902745062
复制
发表时间：
2009-01-01
影响因子：
1.9
通讯作者：
Sipponen, Pentti
中科院分区：
文献类型：
--
作者：
Agreus, Lars;Storskrubb, Tom;Sipponen, Pentti
目标。质子泵抑制剂（PPIs）、H2受体拮抗剂（H2RAs）和抗酸剂/海藻酸盐降低胃酸，从而可能影响正常的胃生理。本研究的目的是研究这些化合物对未感染胃粘膜的瑞典成年人群中血清修饰胃泌素-17 （G-17）和胃泌素原（PGI - PGII）水平的影响。材料和方法。初始样本受试者（n=1000，平均年龄50岁，范围20-80岁）在研究开始前1周和/或3个月完成了一份关于酸抑制药物使用的问卷。所有受试者（n=590）均通过血清生物标志物描述为胃粘膜正常。比较使用抑酸药物组和未使用抑酸药物组血清PGI、PGII和G-17水平。结果。报告使用H2RAs （n=18）或抗酸/海藻酸盐（n=66）的受试者在过去3个月内血清G-17或胃蛋白酶原水平与未使用的受试者（n=471）没有差异。然而，在PPI使用者（n=35）中，G-17和胃蛋白酶原的中位数水平显著（p0.001）高于非PPI使用者：水平约为两倍。然而，在PPI使用者和非PPI使用者之间，或使用抗酸剂/海藻酸盐或H2RAs的人之间，PGI/PGII的比例相似。使用PPIs的受试者血清胃蛋白酶原水平与血清G-17水平呈正相关（p0.01）。结论。在日常临床实践中，ppi可显著提高普通患者空腹血清中G-17和胃蛋白酶原的水平，而抗酸/海藻酸盐或H2RAs则不能。
Objective. Proton-pump inhibitors (PPIs), H2 receptor antagonists (H2RAs) and antacids/alginates reduce intragastric acidity and may thus influence normal gastric physiology. The purpose of this study was to examine the effect of these compounds on serum levels of amidated gastrin-17 (G-17) and pepsinogens (PGI PGII) in a large, random, adult Swedish population sample with uninfected stomach mucosa. Material and methods. The initial sample subjects (n=1000, mean age 50 years, range 20-80 years) completed a questionnaire on the use of acid inhibitory drugs 1 week and/or 3 months before study entry. All subjects (n=590) with normal gastric mucosa as delineated by serum biomarkers were included. Among them, serum levels of PGI, PGII and G-17 were compared between those who used acid inhibitory drugs and those who did not. Results. The serum levels of G-17 or pepsinogens in the subjects who reported use of H2RAs (n=18) or antacid/alginates (n=66) during the previous 3 months did not differ from those in non-users (n=471). However, the median levels of G-17 and pepsinogens were significantly (p0.001) higher among the PPI users (n=35) than among non-users: the levels were approximately doubled. The ratio of PGI/PGII was, however, similar between PPI users and non-users, or those using antacids/alginates or H2RAs. Among subjects using PPIs, the serum levels of pepsinogens correlated positively (p0.01) with the serum levels of G-17. Conclusions. PPIs but not antacids/alginates or H2RAs markedly increase the fasting levels of serum amidated G-17 and pepsinogens among ordinary patients in everyday clinical practice.